EyePoint Pharmaceuticals (EYPT) Operating Income: 2010-2018
Historic Operating Income for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$13.6 million.
- EyePoint Pharmaceuticals' Operating Income fell 125.67% to -$13.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$33.8 million, marking a year-over-year decrease of 94.42%. This contributed to the annual value of -$26.3 million for FY2018, which is 41.44% down from last year.
- EyePoint Pharmaceuticals' Operating Income amounted to -$13.6 million in Q3 2018, which was down 38.56% from -$9.8 million recorded in Q2 2018.
- In the past 5 years, EyePoint Pharmaceuticals' Operating Income ranged from a high of $20.8 million in Q3 2014 and a low of -$13.6 million during Q3 2018.
- Its 3-year average for Operating Income is -$6.4 million, with a median of -$6.0 million in 2017.
- In the last 5 years, EyePoint Pharmaceuticals' Operating Income surged by 659.14% in 2014 and then tumbled by 6,078.72% in 2017.
- Over the past 5 years, EyePoint Pharmaceuticals' Operating Income (Quarterly) stood at -$4.1 million in 2014, then fell by 27.26% to -$5.2 million in 2015, then spiked by 98.21% to -$94,000 in 2016, then slumped by 6,078.72% to -$5.8 million in 2017, then plummeted by 125.67% to -$13.6 million in 2018.
- Its last three reported values are -$13.6 million in Q3 2018, -$9.8 million for Q2 2018, and -$4.7 million during Q1 2018.